You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020159017
Dec 20207007
Jan 20213208
Feb 20214608
Mar 202166011
Apr 20217207
May 202118016
Jun 20210017
Jul 20210013
Aug 2021005
Sep 2021008
Oct 202138025
Nov 202154020
Dec 20214609
Jan 202276012
Feb 202298010
Mar 2022102015
Apr 202294015
May 20227206
Jun 202258015
Jul 20227005
Aug 20227008
Sep 20222804
Oct 20228605
Nov 20229609
Dec 202286010
Jan 202310003
Feb 202310406
Mar 202386010
Apr 20235608
May 20239608
Jun 202314209
Jul 2023106010
Aug 2023116013
Sep 202312606
Oct 202310409
Nov 20238806
Dec 20236404
Jan 20243001
Feb 20247402
Mar 20248205
Apr 20246009
May 20247809
Jun 20244307
Jul 20244207
Aug 20244506
Sep 2024106015
Total32850438